The Bharat Biotech pharma company in a statement about its COVID-19 vaccine, COVAXIN, said that the vaccine was developed with a single minded focus on safety first followed by efficacy.
The company further said, “COVAXIN was the only COVID-19 vaccine in the government of India’s COVID-19 immunisation program to have conducted efficacy trials in India. COVAXIN was evaluated in more than 27,000 subjects as part of its licensure process. It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects. Safety of COVAXIN was also evaluated by the ministry of health, government of India. Ongoing safety monitoring was continued throughout the product life cycle of COVAXIN.”
The company said that all the above studies and safety follow-up activities have demonstrated an excellent safety record for COVAXIN.
